—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Vaxcyte Inc (PCVX) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for PCVX, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sector × region Health care in US: −2.1% week · −2.2% month · +3.3% quarter · +16.4% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.90 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How PCVX has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.90 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Vaxcyte Inc moved 0.90% on average · correlation 0.16 · higher than 83% of US names
  • Beta, last 3 months 0.51 less rate-sensitive lately than over the year
  • On the 10 worst bond days −1.51% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +0.72% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against PCVX on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Vaxcyte Inc

PCVX in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Vaxcyte is a clinical-stage vaccine developer working on conjugate and protein vaccines aimed at bacterial infections. Its lead programmes target pneumococcal disease, with wider-valency candidates meant to cover more strains than existing shots, alongside earlier-stage work on strep, gum disease and dysentery. It holds no approved products yet and depends on trial results to advance its pipeline. It is based in San Carlos, California.
Where it sits in the stack
Vaxcyte carries no seat in our index; it sits in the Healthcare sector, within the biotechnology sleeve of our wider universe, and has no place in any layer of the AI build-out.
Who it is priced against
The diary's peer group has no listed comparison for this name; the market commonly sets it against Pfizer, whose established pneumococcal vaccine occupies the market Vaxcyte's candidates are aimed at.
Why Closelooknet tracks it
It carries a Closelooknet score, with momentum reading as its module of note, though it holds no index seat and has not featured in the diary's quotes or editions.
What the diary watches
The diary watches for trial results on its lead pneumococcal candidates, since a readout would move sentiment well before any change shows up in its score.

Vaxcyte Inc (PCVX) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 34/100 composite (momentum 66, quality 2, valuation —) across 6 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Needham, 2026-10-05

The Street on this name

Analyst actions and the latest print for PCVX from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Needham — target 122 from 110 Target raised to $122 from $110 (+68.7% to spot) 2026-10-05
  • Price target Guggenheim — target 125 Target set to $125 (+121.3% to spot) 2026-10-05

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months

Dividends and capital return

What PCVX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +11.6% in FY2025 139 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Vaxcyte Inc (PCVX)?

Vaxcyte Inc trades as PCVX on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is PCVX in a Closelooknet index?

Not currently — Vaxcyte Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

What is Vaxcyte Inc's Closelooknet composite score?

34 out of 100, with momentum 66, quality 2 and valuation n/a sub-scores, as of 2026-10-07. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does PCVX trade against its moving averages?

Uptrend stack intact: Trades +12.8% vs the 50-day and +20.4% vs the 200-day average, 26.5% below the 52-week high and +67.3% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Vaxcyte Inc compare with its peers?

Against its peer group (Biotechnology · US), Vaxcyte Inc (PCVX) sits 26.5% below its 52-week high, 12.8% above its 50-day average; BeiGene, Ltd. (ONC) is 5.8% below, Regeneron Pharmaceuticals Inc (REGN) is 15.5% below, Caris Life Sciences, Inc. Common Stock (CAI) is 18.4% below. Put any of them next to PCVX in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Vaxcyte Inc trade when bond yields rise?

Over the past year Vaxcyte Inc had a beta of 0.90 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 83% of US names. On the 10 sessions in which long bonds fell most it moved −1.51% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Vaxcyte Inc do?

Vaxcyte is a clinical-stage vaccine developer working on conjugate and protein vaccines aimed at bacterial infections. Its lead programmes target pneumococcal disease, with wider-valency candidates meant to cover more strains than existing shots, alongside earlier-stage work on strep, gum disease and dysentery. It holds no approved products yet and depends on trial results to advance its pipeline. The diary's peer group has no listed comparison for this name; the market commonly sets it against Pfizer, whose established pneumococcal vaccine occupies the market Vaxcyte's candidates are aimed at.

Where does Vaxcyte Inc sit in the AI build-out?

Vaxcyte carries no seat in our index; it sits in the Healthcare sector, within the biotechnology sleeve of our wider universe, and has no place in any layer of the AI build-out. It carries a Closelooknet score, with momentum reading as its module of note, though it holds no index seat and has not featured in the diary's quotes or editions.

Does Vaxcyte Inc pay a dividend?

No cash distribution shows in Vaxcyte Inc’s price series over the last three years. The share count rose 11.6% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Vaxcyte Inc recently?

The most recent analyst action on Vaxcyte Inc on the Closelooknet wire is a price target by Needham on 2026-10-05 (target 122 from 110). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for PCVX, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.